S epsis is a state of systemic acute inflammation driven by the host immune response to a localized or disseminated microbial infection. Sepsis is defined as severe when dysfunction of organ systems remote from the site of infection occurs. This arises from impaired organ perfusion, at least in part, and can culminate in circulatory shock and death. Severe sepsis continues to be a worldwide problem and a burden upon intensive care resources (1) , despite widespread adherence to antisepsis bundles and guidelines (2) , advances in diagnostics, innovations in source control measures, and powerful antibiotics. Although the drive to engineer novel antimicrobial drugs is important, this approach in isolation would overlook the dysfunctional host immune response that exists in severe sepsis. This response is typically hyperinflammatory before progressing into a compensatory immunodeficient state. There is therefore a great need to discover immunomodulatory drugs that can limit multiple organ injury in the context of sepsis. However, this is no mean challenge-the pathogenesis of sepsis is without doubt multifactorial in mechanism, and exactly which molecular mechanistic processes are active at various stages in the inflammatory cascade is only just beginning to be understood.
With this in mind, it is becoming widely accepted that the initiating event in the host inflammatory response to sepsis is the detection of "pathogen-associated molecular patterns" by innate immune cell pattern-recognition receptors (e.g., Tolllike receptors [TLRs]), compounded by the recognition of structurally similar host-derived molecules, "damage-associated molecular patterns" that can also bind and activate the same receptor families. Downstream of the TLRs is a networked series of protein kinases, the mitogen-activated protein kinase (MAPK) signaling pathways, which can exert regulatory effects on the inflammatory response (3). The extracellular signal-regulated kinase-1/2 (ERK1/2) pathway is a major MAPK subfamily and serves as a chain of cellular proteins to communicate cues derived from the cell surface (e.g., TLR signaling) and cytoplasmic receptors. ERK1/2 are activated by the MAPK/ERK kinase-1/2 (MEK1/2), also known as "MKK1/2," which allows residue phosphorylation in the ERK activation loops. Once activated, ERK1/2 are able to phosphorylate many other kinases and transcription factors (4) . ERK1/2 signaling is best known for its contribution to the control of cell proliferation and migration and is important clinically as a therapeutic target site for mutant BRAF cancers (e.g., malignant melanoma) that are dependent on RAF-MEK-ERK signaling for growth. Indeed, all BRAF mutations arising in human cancers are located within the kinase domain, which results in increased BRAF kinase activity and cascade signaling (5) . In recent years, there has been growing evidence to support a prominent role for the ERK signaling pathway in driving the proinflammatory response; this includes the necessity for ERK activation in neutrophil extracellular trap formation (6) , bone marrow-derived macrophage proliferation (7) , and inflammatory cytokine production (3, 8) .
It is therefore timely and rational that Smith et al (9) have chosen to investigate whether there exists a protective effect of MEK/ERK inhibition in a murine model of polymicrobial sepsis. The authors used an experimental mouse model of secondary bacterial peritonitis induced by caecal ligation and puncture (CLP) in adult mice, treated with a intraperitoneal administration of trametinib, a single-agent MEK inhibitor and appropriate experimental controls. This builds on their previous work using a model of systemic inflammation induced by bacterial lipopolysaccharide during which mice were pretreated with trametinib, and work of others that has shown that sepsis-related renal tubule dysfunction can be ameliorated with MEK inhibitor pretreatment (10). The two major strengths of the present work reported in this issue of Critical Care Medicine by Smith et al (11) are the use of a clinically relevant mouse model of abdominal sepsis, and the fact that the authors chose to test whether administration of trametinib at a clinically relevant and delayed time point (6 hr after the induction of CLP sepsis) was effective in reducing organ dysfunction. To increase the translational relevance of the experiments, the experimental protocol also included a crystalloid fluid bolus and β-lactam-based antibiotic 6 hours after the induction of sepsis in both control groups, further simulating the clinical situation.
In any preclinical drug evaluation using experimental models of inflammation, it is important to demonstrate mechanistic relevance of the target in the chosen disease and then specific engagement of that target by the test compound. Smith et al (11) have achieved this to a degree, by first demonstrating an increase in ERK phosphorylation in the renal cortex of mice that had sustained CLP and developed sepsis, and subsequently showing that trametinib blocked ERK activation and downstream phosphorylation. However, we are not shown relevant pharmacokinetics or any detail on the pharmacodynamics of the compound in the disease state, which are likely to be altered in the diseased mice when compared with unaffected mice. Furthermore, we do not see evidence presented regarding the level of inhibition achieved by the specific drug regime that was used. To clarify, to be able to infer that the postulated mechanism and target is indeed the mode of action of the drug in that situation, one might wish to see therapeutic efficacy at near-total but not 100% inhibition, and little or no therapeutic efficacy at low levels of inhibition. In addition, others have recently demonstrated that in stimulated neutrophils, ERK and MEK activation can function independently of each other (8) and thus, in addition to MEK inhibition, a targeted ERK inhibitor may offer added benefits in reducing the multiple organ injury in severe sepsis.
Notwithstanding these technical limitations, administration of trametinib at the single dose used in this article blocked ERK activation during sepsis and successfully reduced renal cortex levels of proinflammatory cytokines and markers of renal tubular injury in CLP mice. Interestingly, Smith et al (11) used intravital video microscopy to observe the preservation of renal microvascular perfusion in trametinib-treated CLP mice. Aside from kidney injury, the authors made efforts to quantify organ dysfunction and cellular injury of other systems, using selected biomarkers, but perhaps not a complete workup of each organ system. Specifically, reduced serum proinflammatory cytokines, alanine aminotransferase, creatine kinase, and lactate dehydrogenase levels were observed in trametinib-treated CLP mice, as well as attenuation of sepsis-inducing hypothermia.
Bridging the translation gap between preclinical rodent models and the clinic is arguably the most important and certainly the most challenging aspect of progressing sepsis research towards patient benefit. The present work by Smith et al (11) is better poised than many to bridge that gap. In this context, because trametinib has U.S. Food and Drug Administration approval in the treatment of melanoma, a significant portion of the developmental groundwork and the framework for approval in other indications, such as sepsis, is already in place. Indeed, other potential therapeutic benefits of ERK inhibition outside the field of oncology have recently emerged, for example, improved insulin resistance in obesity (12) . The present work by Smith et al (11) highlights the potential for trametinib to be useful in yet another clinical context, as a novel immunomodulatory treatment to reduce kidney, and other end-organ injury, in severe sepsis. We await the next move toward the clinic with anticipation.
